Phase III Safety and Immunogenicity Study of 23-valent Pneumococcal Polysaccharide Vaccine: A Double-blind, Randomized and Controlled Clinical Trial With 23-valent Pneumococcal Polysaccharide Vaccine in Healthy Children, Adults, and Elderly
Phase of Trial: Phase III
Latest Information Update: 06 May 2017
At a glance
- Drugs Pneumococcal 23 valent vaccine Sinovac Biotech (Primary)
- Indications Pneumococcal infections
- Focus Therapeutic Use
- Sponsors Sinovac Biotech
- 01 May 2017 Status changed from active, no longer recruiting to completed.
- 15 Jul 2015 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 24 May 2015 Status changed from not yet recruiting to recruiting, as reported by ClinicalTrials.gov.